Moreover, IACS-010759 (hereafter called IACS), a clinically applicable OXPHOS blocker targeting mitochondria complex I (Molina et al, 2018; Yap et al, 2023), inhibited the chondrogenesis of FOP-iMSCs in vitro and suppressed HO in vivo, indicating that OXPHOS is a novel metabolic therapeutic target for FOP treatment. The gene discussed is ACVR1; the disease is fibrodysplasia ossificans progressiva.